These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 7654018)

  • 1. Antiproliferative effects of cyclocreatine on human prostatic carcinoma cells.
    Hoosein NM; Martin KJ; Abdul M; Logothetis CJ; Kaddurah-Daouk R
    Anticancer Res; 1995; 15(4):1339-42. PubMed ID: 7654018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The synthetic phosphagen cyclocreatine phosphate inhibits the growth of a broad spectrum of solid tumors.
    Schimmel L; Khandekar VS; Martin KJ; Riera T; Honan C; Shaw DG; Kaddurah-Daouk R
    Anticancer Res; 1996; 16(1):375-80. PubMed ID: 8615639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclocreatine (1-carboxymethyl-2-iminoimidazolidine) inhibits growth of a broad spectrum of cancer cells derived from solid tumors.
    Lillie JW; O'Keefe M; Valinski H; Hamlin HA; Varban ML; Kaddurah-Daouk R
    Cancer Res; 1993 Jul; 53(13):3172-8. PubMed ID: 8319226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Creatine and phosphocreatine analogs: anticancer activity and enzymatic analysis.
    Bergnes G; Yuan W; Khandekar VS; O'Keefe MM; Martin KJ; Teicher BA; Kaddurah-Daouk R
    Oncol Res; 1996; 8(3):121-30. PubMed ID: 8823808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.
    Butler LM; Agus DB; Scher HI; Higgins B; Rose A; Cordon-Cardo C; Thaler HT; Rifkind RA; Marks PA; Richon VM
    Cancer Res; 2000 Sep; 60(18):5165-70. PubMed ID: 11016644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth Inhibition, G2-M arrest, and apoptosis.
    Tyagi AK; Singh RP; Agarwal C; Chan DC; Agarwal R
    Clin Cancer Res; 2002 Nov; 8(11):3512-9. PubMed ID: 12429642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclocreatine inhibits stimulated motility in tumor cells possessing creatine kinase.
    Mulvaney PT; Stracke ML; Nam SW; Woodhouse E; O'Keefe M; Clair T; Liotta LA; Khaddurah-Daouk R; Schiffmann E
    Int J Cancer; 1998 Sep; 78(1):46-52. PubMed ID: 9724093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell cycle studies of cyclocreatine, a new anticancer agent.
    Martin KJ; Winslow ER; Kaddurah-Daouk R
    Cancer Res; 1994 Oct; 54(19):5160-5. PubMed ID: 7923134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2-Chloroethyl-3-sarcosinamide-1-nitrosourea (SarCNU) inhibits prostate carcinoma cell growth via p53-dependent and p53-independent pathways.
    Huynh H; Nguyen TH; Panasci L; Do P
    Cancer; 2004 Dec; 101(12):2881-91. PubMed ID: 15529313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nontoxic doses of suramin enhance activity of doxorubicin in prostate tumors.
    Zhang Y; Song S; Yang F; Au JL; Wientjes MG
    J Pharmacol Exp Ther; 2001 Nov; 299(2):426-33. PubMed ID: 11602651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen-dependent and -independent human prostate xenograft tumors as models for drug activity evaluation.
    Chen CT; Gan Y; Au JL; Wientjes MG
    Cancer Res; 1998 Jul; 58(13):2777-83. PubMed ID: 9661891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Creatine and cyclocreatine treatment of human colon adenocarcinoma xenografts: 31P and 1H magnetic resonance spectroscopic studies.
    Kristensen CA; Askenasy N; Jain RK; Koretsky AP
    Br J Cancer; 1999 Jan; 79(2):278-85. PubMed ID: 9888469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel therapeutic approach: organic arsenical melarsoprol) alone or with all-trans-retinoic acid markedly inhibit growth of human breast and prostate cancer cells in vitro and in vivo.
    Koshiuka K; Elstner E; Williamson E; Said JW; Tada Y; Koeffler HP
    Br J Cancer; 2000 Jan; 82(2):452-8. PubMed ID: 10646904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin.
    Li Y; Yu DC; Chen Y; Amin P; Zhang H; Nguyen N; Henderson DR
    Cancer Res; 2001 Sep; 61(17):6428-36. PubMed ID: 11522637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the A3 adenosine receptor for cancer therapy: inhibition of prostate carcinoma cell growth by A3AR agonist.
    Fishman P; Bar-Yehuda S; Ardon E; Rath-Wolfson L; Barrer F; Ochaion A; Madi L
    Anticancer Res; 2003; 23(3A):2077-83. PubMed ID: 12894581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate carcinoma response to cytotoxic therapy: in vivo resistance.
    Teicher BA; Kakeji Y; Ara G; Herbst RS; Northey D
    In Vivo; 1997; 11(6):453-61. PubMed ID: 9509295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 20-Cyclopropyl-cholecalciferol vitamin D3 analogs: a unique class of potent inhibitors of proliferation of human prostate, breast and myeloid leukemia cell lines.
    Koike M; Koshizuka K; Kawabata H; Yang R; Taub HE; Said J; Uskokovic M; Tsuruoka N; Koeffler HP
    Anticancer Res; 1999; 19(3A):1689-97. PubMed ID: 10470102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flavopiridol (L86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells.
    Drees M; Dengler WA; Roth T; Labonte H; Mayo J; Malspeis L; Grever M; Sausville EA; Fiebig HH
    Clin Cancer Res; 1997 Feb; 3(2):273-9. PubMed ID: 9815683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of LNCaP prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase.
    Igawa T; Lin FF; Rao P; Lin MF
    Prostate; 2003 Jun; 55(4):247-58. PubMed ID: 12712404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of creatine analogues as a new class of anticancer agents using freshly explanted human tumor cells.
    Martin KJ; Chen SF; Clark GM; Degen D; Wajima M; Von Hoff DD; Kaddurah-Daouk R
    J Natl Cancer Inst; 1994 Apr; 86(8):608-13. PubMed ID: 8145276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.